

Fill in this information to identify the case:

Debtor 1 CPA Global Limited

Debtor 2
(Spouse, if filing) _____

United States Bankruptcy Court for the: Northern District of Texas

Case number 24-840040-sgi/11

Official Form 410

Proof of Claim

04/22

Read the instructions before filling out this form. This form is for making a claim for payment in a bankruptcy case. Do not use this form to make a request for payment of an administrative expense. Make such a request according to 11 U.S.C. § 503.

Filers must leave out or redact information that is entitled to privacy on this form or on any attached documents. Attach redacted copies of any documents that support the claim, such as promissory notes, purchase orders, invoices, itemized statements of running accounts, contracts, judgments, mortgages, and security agreements. Do not send original documents; they may be destroyed after scanning. If the documents are not available, explain in an attachment.

A person who files a fraudulent claim could be fined up to \$500,000, imprisoned for up to 5 years, or both. 18 U.S.C. §§ 152, 157, and 3571.

Fill in all the information about the claim as of the date the case was filed. That date is on the notice of bankruptcy (Form 309) that you received.

Part 1: Identify the Claim

1. Who is the current creditor?	<u>CPA Global Limited</u> Name of the current creditor (the person or entity to be paid for this claim)	
	Other names the creditor used with the debtor _____	
2. Has this claim been acquired from someone else?	<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes. From whom? _____	
3. Where should notices and payments to the creditor be sent? Federal Rule of Bankruptcy Procedure (FRBP) 2002(g)	Where should notices to the creditor be sent?	Where should payments to the creditor be sent? (if different)
	<u>CPA Global Limited</u> Name <u>789 E. Eisenhower Parkway</u> Number Street <u>Ann Arbor MI 48108</u> City State ZIP Code Contact phone <u>01204067062</u> Contact email <u>finance@cpaglobal.com</u>	<u>CPA Global Limited</u> Name <u>PO Box 18263</u> Number Street <u>Palatine IL 60055</u> City State ZIP Code Contact phone <u>01204067062</u> Contact email <u>finance@cpaglobal.com</u>
Uniform claim identifier for electronic payments in chapter 13 (if you use one): -----		
4. Does this claim amend one already filed?	<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes. Claim number on court claims registry (if known) _____ Filed on <u>MM / DD / YYYY</u>	
5. Do you know if anyone else has filed a proof of claim for this claim?	<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes. Who made the earlier filing? _____	



KURTZMAN CARSON CONSULTANTS

RECEIVED

MAY 20 2024

Part 2: Give Information About the Claim as of the Date the Case Was Filed

6. Do you have any number you use to identify the debtor? No
 Yes. Last 4 digits of the debtor's account or any number you use to identify the debtor: 3 8 5 6

7. How much is the claim? \$ 31,023.78. Does this amount include interest or other charges?
 No
 Yes. Attach statement itemizing interest, fees, expenses, or other charges required by Bankruptcy Rule 3001(c)(2)(A).

8. What is the basis of the claim? Examples: Goods sold, money loaned, lease, services performed, personal injury or wrongful death, or credit card.
Attach redacted copies of any documents supporting the claim required by Bankruptcy Rule 3001(c).
Limit disclosing information that is entitled to privacy, such as health care information.
Patent Renewal Services

9. Is all or part of the claim secured? No
 Yes. The claim is secured by a lien on property.
Nature of property:
 Real estate. If the claim is secured by the debtor's principal residence, file a *Mortgage Proof of Claim Attachment* (Official Form 410-A) with this *Proof of Claim*.
 Motor vehicle
 Other. Describe: _____
Basis for perfection: _____
Attach redacted copies of documents, if any, that show evidence of perfection of a security interest (for example, a mortgage, lien, certificate of title, financing statement, or other document that shows the lien has been filed or recorded.)
Value of property: \$ _____
Amount of the claim that is secured: \$ _____
Amount of the claim that is unsecured: \$ _____ (The sum of the secured and unsecured amounts should match the amount in line 7.)
Amount necessary to cure any default as of the date of the petition: \$ _____
Annual Interest Rate (when case was filed) _____ %
 Fixed
 Variable

10. Is this claim based on a lease? No
 Yes. Amount necessary to cure any default as of the date of the petition. \$ _____

11. Is this claim subject to a right of setoff? No
 Yes. Identify the property: _____

RECEIVED

MAY 20 2024

KURTZMAN CARSON CONSULTANTS

12. Is all or part of the claim entitled to priority under 11 U.S.C. § 507(a)?

No

Yes. Check one:

Amount entitled to priority

A claim may be partly priority and partly nonpriority. For example, in some categories, the law limits the amount entitled to priority.

Domestic support obligations (including alimony and child support) under 11 U.S.C. § 507(a)(1)(A) or (a)(1)(B).

\$ _____

Up to \$3,350* of deposits toward purchase, lease, or rental of property or services for personal, family, or household use. 11 U.S.C. § 507(a)(7).

\$ _____

Wages, salaries, or commissions (up to \$15,150* earned within 180 days before the bankruptcy petition is filed or the debtor's business ends, whichever is earlier). 11 U.S.C. § 507(a)(4).

\$ _____

Taxes or penalties owed to governmental units. 11 U.S.C. § 507(a)(8).

\$ _____

Contributions to an employee benefit plan. 11 U.S.C. § 507(a)(5).

\$ _____

Other. Specify subsection of 11 U.S.C. § 507(a)() that applies.

\$ _____

* Amounts are subject to adjustment on 4/01/25 and every 3 years after that for cases begun on or after the date of adjustment.

Part 3: Sign Below

The person completing this proof of claim must sign and date it. FRBP 9011(b).

If you file this claim electronically, FRBP 5005(a)(2) authorizes courts to establish local rules specifying what a signature is.

A person who files a fraudulent claim could be fined up to \$500,000, imprisoned for up to 5 years, or both. 18 U.S.C. §§ 152, 157, and 3571.

Check the appropriate box:

I am the creditor.

I am the creditor's attorney or authorized agent.

I am the trustee, or the debtor, or their authorized agent. Bankruptcy Rule 3004.

I am a guarantor, surety, endorser, or other codebtor. Bankruptcy Rule 3005.

I understand that an authorized signature on this *Proof of Claim* serves as an acknowledgment that when calculating the amount of the claim, the creditor gave the debtor credit for any payments received toward the debt.

I have examined the information in this *Proof of Claim* and have a reasonable belief that the information is true and correct.

I declare under penalty of perjury that the foregoing is true and correct.

04/26/2024

Executed on date

MM / DD / YYYY



8

Signature

Print the name of the person who is completing and signing this claim:

Mansi Wadhwa

Name

First name

Middle name

Last name

Lead Collections Specialist

Title

Company

CPA Global Limited

Identify the corporate servicer as the company if the authorized agent is a servicer.

Address

789 E. Eisenhower Parkway

Number Street

Ann Arbor

MI

48108

City

State

ZIP Code

Contact phone

01204067062

Email finance@cpaglobal.com


RECEIVED

MAY 20 2024

KURTZMAN CARSON CONSULTANTS

CPA GLOBAL

Part of Clarivate



Invoice U483121

Eiger Biopharmaceuticals Inc
Attn: Matthew Bys
2155 Park Boulevard
350 Cambridge Avenue
Suite 350
Palo Alto CA 94306 USA

This Invoice has been issued either in line with your contract terms, or in response to renewal instructions, for the following 53 Patent cases.

The costs on this Invoice may differ from the estimated costs in the Renewal Notice due to fluctuations in exchange rates, official charge increases and any applicable late charges.

You should note that interest will be charged on any amounts overdue at the rate of 1% per month or part thereof.

Total amount due
US\$ 48,251.16

You must allow time for your payment to clear by 29 March 2024.

Purchase Order Number: 3010

28 February 2024

Eiger Biopharmaceuticals, Inc.

CPA Global account number: 2493856

Account currency: US Dollar

We are here to help

North America Customer Engagement

Email: finance@cpaglobal.com

Phone: 1-866-739-2239

Operated by

CPA Global
789 E. Eisenhower Parkway
Ann Arbor
MI 48108
USA

Note: Please do not make cheques payable to CPA Global North America LLC.

Please let us know if you would like to:

- learn about RENEW, our online patents and designs portfolio management tool
- receive the information in this document as a data file in the future
- have your cases listed in a different order in the future
- change your contact details

Service location

Please note that CPA Global Limited's renewals service is performed outside of the US. Form W8-BEN is available upon request.

How to pay this Invoice

Please pay using one of the methods below and provide details of any credit being used.

Bank transfer

HSBC Bank Plc	Sort code	40-05-15
8 Canada Square	Account Number	69417697
London	Account Name	CPA Global Limited
E14 5HQ	SWIFT Code	MIDLGB22XXX
	IBAN Number	GB24MIDL40051569417697

The transaction reference should include your CPA Global account and invoice number.

Cheque

Cheques must be made payable to CPA Global Limited. Please reference your CPA Global Account number or Invoice number on the cheque. For convenience, please send cheques to our North American affiliate at the following address for onward provision to CPA Global Limited.

CPA Global Limited
PO Box 18263
Palatine, IL 60055- 8263
USA

Cheques may also be sent directly to CPA Global Limited to the address shown at the foot of this invoice.

ACH Payment

HSBC Bank USA Na	Account Number: 783009631
425 5th Avenue, New York, NY 10018	
Account Name: CPA Global Limited	
Routing Number: 022000020	
ABA Number: 021001088	
SWIFT Code: MRMDUS33	

CPA GLOBAL

Part of Clarivate

Date 28 February 2024 CPA Global account number 2493856 Client name Eiger Biopharmaceuticals, Inc.

Invoice U483121 continued

Total amount due
US\$ 48,251.16

Charges

Official Charge*

This represents the amount we pay to relevant registries in each jurisdiction and which may vary from time to time.

Country Charge*

This charge relates to the infrastructure, CPA Global personnel and third parties (as appropriate) required in order to execute a renewal in a particular jurisdiction. CPA Global maintains a schedule of applicable Country Charges (which may be updated from time to time), a current copy of which is available on request.

Administration Charge (also referred to as Service Charge)

This charge relates to the systems and CPA Global personnel that determine which patents need to be renewed in which jurisdictions at which point in time.

* The Official Charge and Country Charge as well as any other sums of money that may at any time require to be converted from one currency into the currency in which we invoice you will be converted at our rates and are subject to a charge for funds management e.g. managing global transactions, currency risk exposure, credit risk and financing renewal payments.

For more information please refer to your written contract (if applicable), or the terms and conditions on your Renewal Notice or contact us.

Austria Patent number 3285768 Renewal date 21 Apr 2024 Annuity 09

Invoice item number	Type	Application number	Proprietor	Cost
0001	Patent	16783855.6	EIGER BIOPHARMACEUTICALS, INC.	US\$ 1,022.70
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
PHARMACEUTICAL COMPOSITIONS COMPRIS		923405	097854-1210092	
Official Charge	Country Charge	Administration Charge		
US\$ 620.37	US\$ 202.33	US\$ 200.00		

Belgium Patent number 3285768 Renewal date 21 Apr 2024 Annuity 09

Invoice item number	Type	Application number	Proprietor	Cost
0002	Patent	16783855.6	EIGER BIOPHARMACEUTICALS, INC.	US\$ 692.92
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
PHARMACEUTICAL COMPOSITIONS COMPRIS		923406	097854-1210093	
Official Charge	Country Charge	Administration Charge		
US\$ 245.46	US\$ 247.46	US\$ 200.00		

Bulgaria Patent number 3285768 Renewal date 21 Apr 2024 Annuity 09

Invoice item number	Type	Application number	Proprietor	Cost
0003	Patent	16783855.6	EIGER BIOPHARMACEUTICALS, INC.	US\$ 820.99
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
PHARMACEUTICAL COMPOSITIONS COMPRIS		923407	097854-1210094	
Official Charge	Country Charge	Administration Charge		
US\$ 299.64	US\$ 321.35	US\$ 200.00		

Czechia Patent number 3285768 Renewal date 21 Apr 2024 Annuity 09

Invoice item number	Type	Application number	Proprietor	Cost
0004	Patent	16783855.6	EIGER BIOPHARMACEUTICALS, INC.	US\$ 602.77
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
PHARMACEUTICAL COMPOSITIONS COMPRIS		923408	097854-1210095	
Official Charge	Country Charge	Administration Charge		
US\$ 176.59	US\$ 226.18	US\$ 200.00		

CPA GLOBAL

Part of Clarivate

Date 28 February 2024 CPA Global account number 2493856 Client name Eiger Biopharmaceuticals, Inc.

Invoice U483121 continued

Denmark Patent number 3285768 Renewal date 21 Apr 2024 Annuity 09

Invoice item number	Type	Application number	Proprietor	Cost
0005	Patent	16783855.6	EIGER BIOPHARMACEUTICALS, INC.	US\$ 920.53
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
PHARMACEUTICAL COMPOSITIONS COMPRIS		923409	097854-1210097	
Official Charge	Country Charge	Administration Charge		
US\$ 442.04	US\$ 278.49	US\$ 200.00		

France Patent number 3285768 Renewal date 21 Apr 2024 Annuity 09

Invoice item number	Type	Application number	Proprietor	Cost
0006	Patent	16783855.6	EIGER BIOPHARMACEUTICALS, INC.	US\$ 696.15
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
PHARMACEUTICAL COMPOSITIONS COMPRIS		923416	097854-1210099	
Official Charge	Country Charge	Administration Charge		
US\$ 267.79	US\$ 228.36	US\$ 200.00		

Hungary Patent number 3285768 Renewal date 21 Apr 2024 Annuity 09

Invoice item number	Type	Application number	Proprietor	Cost
0007	Patent	16783855.6	EIGER BIOPHARMACEUTICALS, INC.	US\$ 999.27
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
PHARMACEUTICAL COMPOSITIONS COMPRIS		923417	097854-1210101	
Official Charge	Country Charge	Administration Charge		
US\$ 570.69	US\$ 228.58	US\$ 200.00		

Romania Patent number 3285768 Renewal date 21 Apr 2024 Annuity 09

Invoice item number	Type	Application number	Proprietor	Cost
0008	Patent	16783855.6	EIGER BIOPHARMACEUTICALS, INC.	US\$ 941.62
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
PHARMACEUTICAL COMPOSITIONS COMPRIS		923419	097854-1210103	
Official Charge	Country Charge	Administration Charge		
US\$ 386.80	US\$ 354.82	US\$ 200.00		

Switzerland Patent number 3285768 Renewal date 21 Apr 2024 Annuity 09

Invoice item number	Type	Application number	Proprietor	Cost
0009	Patent	16783855.6	EIGER BIOPHARMACEUTICALS, INC.	US\$ 949.85
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
PHARMACEUTICAL COMPOSITIONS COMPRIS		923421	097854-1210105	
Official Charge	Country Charge	Administration Charge		
US\$ 344.94	US\$ 404.91	US\$ 200.00		

Great Britain Patent number 3285768 Renewal date 21 Apr 2024 Annuity 09

Invoice item number	Type	Application number	Proprietor	Cost
0010	Patent	16783855.6	EIGER BIOPHARMACEUTICALS, INC.	US\$ 640.53
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
PHARMACEUTICAL COMPOSITIONS COMPRIS		923423	097854-1210100	
Official Charge	Country Charge	Administration Charge		
US\$ 260.16	US\$ 180.37	US\$ 200.00		

CPA GLOBAL

Part of Clarivate

Date 28 February 2024 CPA Global account number 2493856 Client name Eiger Biopharmaceuticals, Inc.

Invoice U483121 continued

Spain Patent number 16783855.6 Renewal date 21 Apr 2024 Annuity 09

Invoice item number	Type	Application number	Proprietor	Cost
0011	Patent	16783855.6	EIGER BIOPHARMACEUTICALS, INC.	US\$ 718.87
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
PHARMACEUTICAL COMPOSITIONS COMPRIS		923411	097854-1210098	
Official Charge	Country Charge	Administration Charge		
US\$ 254.79	US\$ 264.08	US\$ 200.00		

Sweden Patent number 16783855.6 Renewal date 21 Apr 2024 Annuity 09

Invoice item number	Type	Application number	Proprietor	Cost
0012	Patent	16783855.6	EIGER BIOPHARMACEUTICALS, INC.	US\$ 790.09
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
PHARMACEUTICAL COMPOSITIONS COMPRIS		923420	097854-1210104	
Official Charge	Country Charge	Administration Charge		
US\$ 386.42	US\$ 203.67	US\$ 200.00		

Türkiye Patent number 2021/00732 Renewal date 21 Apr 2024 Annuity 09

Invoice item number	Type	Application number	Proprietor	Cost
0013	Patent	16783855.6	EIGER BIOPHARMACEUTICALS, INC.	US\$ 409.82
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
PHARMACEUTICAL COMPOSITIONS COMPRIS		923422	097854-1210106	
Official Charge	Country Charge	Administration Charge		
US\$ 172.69	US\$ 37.13	US\$ 200.00		

China Patent number 201680023413.9 Renewal date 21 Apr 2024 Annuity 09

Invoice item number	Type	Application number	Proprietor	Cost
0014	Patent	201680023413.9	EIGER BIOPHARMACEUTICALS, INC.	US\$ 853.39
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
PHARMACEUTICAL COMPOSITIONS COMPRIS		776861	097854-1064652	
Official Charge	Country Charge	Administration Charge		
US\$ 383.82	US\$ 269.57	US\$ 200.00		

Germany Patent number 602016050656.4 Renewal date 21 Apr 2024 Annuity 09

Invoice item number	Type	Application number	Proprietor	Cost
0015	Patent	16783855.6	EIGER BIOPHARMACEUTICALS, INC.	US\$ 1,006.71
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
PHARMACEUTICAL COMPOSITIONS COMPRIS		923410	097854-1210096	
Official Charge	Country Charge	Administration Charge		
US\$ 520.70	US\$ 286.01	US\$ 200.00		

Italy Patent number 502021000005546 Renewal date 21 Apr 2024 Annuity 09

Invoice item number	Type	Application number	Proprietor	Cost
0016	Patent	16783855.6	EIGER BIOPHARMACEUTICALS, INC.	US\$ 792.81
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
PHARMACEUTICAL COMPOSITIONS COMPRIS		923418	097854-1210102	
Official Charge	Country Charge	Administration Charge		
US\$ 297.55	US\$ 295.26	US\$ 200.00		

CPA GLOBAL

Part of Clarivate

Date 28 February 2024 CPA Global account number 2493856 Client name Eiger Biopharmaceuticals, Inc.

Invoice U483121 continued

Greece Patent number 3100081 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0017	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 762.35
Reference				
TREATMENT OF HEPATITIS DELTA VIRUS		Kilpatrick Townsend & Stockton LLP case code 860596	File number 097854-1140306	
Official Charge				
US\$ 282.67	Country Charge US\$ 279.68	Administration Charge US\$ 200.00		

Austria Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0018	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 1,271.90
Reference				
TREATMENT OF HEPATITIS DELTA VIRUS		Kilpatrick Townsend & Stockton LLP case code 860586	File number 097854-1140293	
Official Charge				
US\$ 776.59	Country Charge US\$ 295.31	Administration Charge US\$ 200.00		

Belgium Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0019	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 722.69
Reference				
TREATMENT OF HEPATITIS DELTA VIRUS		Kilpatrick Townsend & Stockton LLP case code 860587	File number 097854-1140294	
Official Charge				
US\$ 275.23	Country Charge US\$ 247.46	Administration Charge US\$ 200.00		

Bulgaria Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0020	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 915.59
Reference				
TREATMENT OF HEPATITIS DELTA VIRUS		Kilpatrick Townsend & Stockton LLP case code 860588	File number 097854-1140295	
Official Charge				
US\$ 394.24	Country Charge US\$ 321.35	Administration Charge US\$ 200.00		

Cyprus Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0021	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 805.49
Reference				
TREATMENT OF HEPATITIS DELTA VIRUS		Kilpatrick Townsend & Stockton LLP case code 860589	File number 097854-1140297	
Official Charge				
US\$ 267.79	Country Charge US\$ 337.70	Administration Charge US\$ 200.00		

Czechia Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0022	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 661.64
Reference				
TREATMENT OF HEPATITIS DELTA VIRUS		Kilpatrick Townsend & Stockton LLP case code 860590	File number 097854-1140298	
Official Charge				
US\$ 235.46	Country Charge US\$ 226.18	Administration Charge US\$ 200.00		

CPA GLOBAL

Part of Clarivate

Date 28 February 2024 CPA Global account number 2493856 Client name Eiger Biopharmaceuticals, Inc.

Invoice U483121 continued

Denmark Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0023	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 974.40
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860591	097854-1140300	
Official Charge	Country Charge	Administration Charge		
US\$ 495.91	US\$ 278.49	US\$ 200.00		

Estonia Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0024	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 829.59
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860592	097854-1140301	
Official Charge	Country Charge	Administration Charge		
US\$ 304.97	US\$ 324.62	US\$ 200.00		

Finland Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0025	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 1,060.65
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860593	097854-1140303	
Official Charge	Country Charge	Administration Charge		
US\$ 639.73	US\$ 220.92	US\$ 200.00		

France Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0026	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 755.65
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860594	097854-1140304	
Official Charge	Country Charge	Administration Charge		
US\$ 327.29	US\$ 228.36	US\$ 200.00		

Hungary Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0027	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 999.27
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860597	097854-1140307	
Official Charge	Country Charge	Administration Charge		
US\$ 570.69	US\$ 228.58	US\$ 200.00		

Iceland Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0028	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 872.43
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860598	097854-1140309	
Official Charge	Country Charge	Administration Charge		
US\$ 276.72	US\$ 395.71	US\$ 200.00		

CPA GLOBAL

Part of Clarivate

Date 28 February 2024 CPA Global account number 2493856 Client name Eiger Biopharmaceuticals, Inc.

Invoice U483121 continued

Ireland Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0029	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 852.34
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860599	097854-1140308	
Official Charge	Country Charge	Administration Charge		
US\$ 327.29	US\$ 325.05	US\$ 200.00		

Latvia Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0030	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 1,148.87
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860601	097854-1140314	
Official Charge	Country Charge	Administration Charge		
US\$ 476.06	US\$ 472.81	US\$ 200.00		

Lithuania Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0031	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 978.08
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860603	097854-1140312	
Official Charge	Country Charge	Administration Charge		
US\$ 343.67	US\$ 434.41	US\$ 200.00		

Luxembourg Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0032	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 606.14
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860604	097854-1140313	
Official Charge	Country Charge	Administration Charge		
US\$ 194.89	US\$ 211.25	US\$ 200.00		

Monaco Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0033	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 805.88
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860605	097854-1140315	
Official Charge	Country Charge	Administration Charge		
US\$ 275.23	US\$ 330.65	US\$ 200.00		

Netherlands Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0034	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 1,032.38
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860606	097854-1140316	
Official Charge	Country Charge	Administration Charge		
US\$ 595.08	US\$ 237.30	US\$ 200.00		

CPA GLOBAL

Part of Clarivate

Date 28 February 2024 CPA Global account number 2493856 Client name Eiger Biopharmaceuticals, Inc.

Invoice U483121 continued

Norway Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0035	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 938.45
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860607	097854-1140317	
Official Charge	Country Charge	Administration Charge		
US\$ 547.02	US\$ 191.43	US\$ 200.00		

Poland Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0036	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 828.50
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860608	097854-1140318	
Official Charge	Country Charge	Administration Charge		
US\$ 224.51	US\$ 403.99	US\$ 200.00		

Portugal Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0037	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 1,204.61
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860609	097854-1140319	
Official Charge	Country Charge	Administration Charge		
US\$ 605.54	US\$ 399.07	US\$ 200.00		

Romania Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0038	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 1,016.76
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860610	097854-1140320	
Official Charge	Country Charge	Administration Charge		
US\$ 416.57	US\$ 400.19	US\$ 200.00		

Slovakia Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0039	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 792.12
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860611	097854-1140323	
Official Charge	Country Charge	Administration Charge		
US\$ 296.06	US\$ 296.06	US\$ 200.00		

Slovenia Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0040	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 640.37
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860612	097854-1140322	
Official Charge	Country Charge	Administration Charge		
US\$ 163.65	US\$ 276.72	US\$ 200.00		

CPA GLOBAL

Part of Clarivate

Date 28 February 2024 CPA Global account number 2493856 Client name Eiger Biopharmaceuticals, Inc.

Invoice U483121 continued

Switzerland Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0041	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 1,012.56
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860615	097854-1140296	
Official Charge		Country Charge	Administration Charge	
US\$ 407.65	US\$ 404.91	US\$ 200.00		

Great Britain Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0042	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 675.22
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860617	097854-1140305	
Official Charge		Country Charge	Administration Charge	
US\$ 294.85	US\$ 180.37	US\$ 200.00		

Spain Patent number 15785846.5 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0043	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 829.15
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860613	097854-1140302	
Official Charge		Country Charge	Administration Charge	
US\$ 327.89	US\$ 301.26	US\$ 200.00		

Sweden Patent number 15785846.5 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0044	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 830.06
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860614	097854-1140321	
Official Charge		Country Charge	Administration Charge	
US\$ 426.39	US\$ 203.67	US\$ 200.00		

Europe Patent application number 19162000.4 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0045	Patent	19162000.4	EIGER BIOPHARMACEUTICALS, INC.	US\$ 2,980.55
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		852526	097854-1131064	
Official Charge		Country Charge	Administration Charge	
US\$ 2,640.70	US\$ 139.85	US\$ 200.00		

Türkiye Patent number TR201908065T4 Renewal date 01 May 2024 Annuity 10

Invoice item number	Type	Application number	Proprietor	Cost
0046	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 422.16
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860616	097854-1140324	
Official Charge		Country Charge	Administration Charge	
US\$ 185.03	US\$ 37.13	US\$ 200.00		

CPA GLOBAL

Part of Clarivate

Date 28 February 2024 CPA Global account number 2493856 Client name Eiger Biopharmaceuticals, Inc.

Invoice U483121 continued

China Patent number **201580023585.1** Renewal date **01 May 2024** Annuity **10**

Invoice item number	Type	Application number	Proprietor	Cost
0047	Patent	201580023585.1	EIGER BIOPHARMACEUTICALS, INC.	US\$ 1,237.19
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		732622	097854-1028092	
Official Charge	Country Charge	Administration Charge		
US\$ 767.62	US\$ 269.57	US\$ 200.00		

Germany Patent number **602015026839.3** Renewal date **01 May 2024** Annuity **10**

Invoice item number	Type	Application number	Proprietor	Cost
0048	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 1,144.33
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860595	097854-1140299	
Official Charge	Country Charge	Administration Charge		
US\$ 639.73	US\$ 304.60	US\$ 200.00		

Italy Patent number **502019000037764** Renewal date **01 May 2024** Annuity **10**

Invoice item number	Type	Application number	Proprietor	Cost
0049	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 856.03
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860600	097854-1140310	
Official Charge	Country Charge	Administration Charge		
US\$ 342.18	US\$ 313.85	US\$ 200.00		

U.S.A. Patent number **10828283** Renewal date **10 May 2024** Annuity **01**

Invoice item number	Type	Application number	Proprietor	Cost
0050	Small Entity	16/052386	EIGER BIOPHARMACEUTICALS, INC.	US\$ 1,000.00
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF HEPATITIS DELTA VIRUS		819090	097854-1098916	
Official Charge	Country Charge	Administration Charge		
US\$ 800.00	US\$ 0.00	US\$ 200.00		

U.S.A. Patent number **10835496** Renewal date **17 May 2024** Annuity **01**

Invoice item number	Type	Application number	Proprietor	Cost
0051	Small Entity	15/567444	EIGER BIOPHARMACEUTICALS, INC.	US\$ 1,000.00
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
PHARMACEUTICAL COMPOSITIONS COMPRIS		777350	097854-1064982	
Official Charge	Country Charge	Administration Charge		
US\$ 800.00	US\$ 0.00	US\$ 200.00		

Europe Patent application number **22744570.7** Renewal date **21 Jun 2024** Annuity **03**

Invoice item number	Type	Application number	Proprietor	Cost
0052	Patent	22744570.7	EIGER BIOPHARMACEUTICALS, INC.	US\$ 1,366.38
Reference		Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF CONGENITAL HYPERINSULI		1113067	097854-1416394	
Official Charge	Country Charge	Administration Charge		
US\$ 1,026.53	US\$ 139.85	US\$ 200.00		

CPA GLOBAL

Part of Clarivate

Date 28 February 2024 CPA Global account number 2493856 Client name Eiger Biopharmaceuticals, Inc.

Invoice U483121 continued

Canada Patent application number PCT/US22/034415 Renewal date 21 Jun 2024 Annuity 03

Invoice item number	Type	Proprietor	Cost
0053	Small Entity	EIGER BIOPHARMACEUTICALS, INC.	US\$ 562.36
Reference	Kilpatrick Townsend & Stockton LLP case code	File number	
TREATMENT OF CONGENITAL HYPERINSULI	1113066	097854-1416393	
Official Charge	Country Charge	Administration Charge	
US\$ 127.95	US\$ 234.41	US\$ 200.00	

Notes

Irrespective of the Entity size CPA Global pay Canadian patent annuities as Large Entity

This page is intentionally left blank

CPA GLOBAL®

Renewal Services Agreement

Patents and Designs
Quarterly Automatic Payment Service

Issue Date: August 28, 2017

Elger Biopharmaceuticals, Inc.

350 Cambridge Avenue
Suite 350
Palo Alto, CA 94306

CPA Global Limited
Company Number 93743

Liberation House
Castle Street
Jersey JE1 1BL
Channel Islands

CPA GLOBAL[®]

TABLE OF CONTENTS

OPERATING PROCEDURES	3
1. SERVICE DESCRIPTION	3
2. DATA EXCHANGE	3
3. ON-GOING COMMUNICATION AND DATA MANAGEMENT	3
4. SERVICE CHARGE	4
5. CREDIT PERIOD	4
6. CURRENCY FOR INVOICE AND PAYMENT	4
7. CPA START PAY DATE	4
8. WORKFLOW DIAGRAM	5
9. KEY DATES	6
TERMS AND CONDITIONS OF SUPPLY OF CPA GLOBAL LIMITED	7
1. APPLICATION	7
2. FORMATION OF CONTRACT	7
3. INSTRUCTIONS	7
4. AGENTS AND OTHER SUB-CONTRACTORS	7
5. CHARGES	7
6. PAYMENT	8
7. CONFIDENTIALITY	8
8. RECORDS	8
9. TERMINATION	8
10. FORCE MAJEURE	8
11. ASSIGNMENT	9
12. GOVERNING LAW	9
13. NOTICE AND COMMUNICATIONS	9

CPA GLOBALSM

OPERATING PROCEDURES

1. SERVICE DESCRIPTION

- 1.1 We will handle the payment of your patent and design renewal fees.
- 1.2 We will send you a consolidated quarterly renewal notice approximately three months in advance of the beginning of the renewal due period as set out in the table under the heading "Key Dates". The renewal notice will be sent by paper and/or via electronic file.
- 1.3 You will inform us of cases that should be abandoned by the last date for abandonment as set out in the table under the heading "Key Dates". Abandon instructions may be sent to us either using CPA Direct, our online service, via electronic batch transfer or via fax or mail. We will confirm an abandon instruction by sending a remove acknowledgement report. If we have not received an abandon instruction we will instruct payment of the renewal fee.
- 1.4 We will send you a quarterly invoice. The invoice will be sent approximately one month prior to the beginning of the renewal quarter. The invoice will be sent on paper and via electronic file (if required).
- 1.5 If an abandon instruction is received after the relevant invoice has been issued, we will issue a credit only if we have not already actioned the renewal.
- 1.6 We will store all official receipts for you. A copy may be requested at any time.

2. DATA EXCHANGE

- 2.1 Your patent firm will provide us with an initial data set for all granted and pending cases.
- 2.2 We will analyse the data to determine data quality and send your patent firm any queries, where we identify difficulties. You will be responsible for diligently working with your patent firm to resolve all data discrepancies in a timely manner. Your patent firm will communicate the resolution of these discrepancies to us.
- 2.3 Once the discrepancies are resolved, we will load the data onto the live system and provide your patent firm with a portfolio file of all cases loaded. They will review this portfolio file and approve the contents.

3. ON-GOING COMMUNICATION AND DATA MANAGEMENT


- 3.1 On a regular basis, your patent firm will send us data for new cases as well as updates to existing case data in a mutually agreed format.
- 3.2 We will update data transferred by your patent firm to us and provide your patent firm with details of the changes on paper or via standard electronic files.

CPA GLOBAL™

- 3.3 Your patent firm will update their records in accordance with our instructions from time to time.
- 3.4 We will update your data on our system based on data received from third parties and send your patent firm paper input reports. Your patent firm will check the contents of the reports and update your data accordingly.
- 3.5 In the event your patent firm ceases to be responsible for any obligations under this clause 3, it shall be incumbent on you to notify us and fulfil their obligations yourself in the interim until we mutually agree on how data reporting will be handled in the future.
4. **SERVICE CHARGE**
- 4.1 We will charge you USD 200 for each renewal (the "Service Charge"). We will give you not less than 6 months' notice of any increase in our Service Charge. Additional charges are described in Section 5 of the Terms and Conditions of Supply attached hereto.
5. **CREDIT PERIOD**
- 5.1 Your credit period is 30 days from the date that our invoice is issued.
6. **CURRENCY FOR INVOICE AND PAYMENT**
- 6.1 The currency for invoice and payment will be US Dollars.
7. **CPA START PAY DATE**
- 7.1 We will begin making payments pursuant to the terms of this agreement beginning with renewals due on or after October 1, 2017, provided you have signed and returned this agreement to us within 30 days of the issue date we have specified on the first page of this agreement. If you fail to return a signed agreement to us by such date, we reserve the right to delay the date in which we initiate your automatic service under the terms of this Agreement. There will be no interruption in your service during the transition from your current instruct account to your automatic account.

CPA GLOBAL™

8. WORKFLOW DIAGRAM



CPA GLOBAL™

9. KEY DATES

Patent and design renewals due	Renewal notice date ¹	Last date for abandonment ²	CPA Invoice date
Quarter 1 January February March	September	20 November	28 November
Quarter 2 April May June	December	20 February	28 February
Quarter 3 July August September	March	20 May	28 May
Quarter 4 October November December	June	20 August	28 August

1. We will send you only one renewal notice approximately 3 months prior to the due period.
2. This is the last date on which we can accept your abandon instruction. If abandon instructions are received after this date we may not be able to refund any cost of renewal.

CPA GLOBAL

TERMS AND CONDITIONS OF SUPPLY OF CPA GLOBAL LIMITED

1. APPLICATION

1.1 These conditions shall govern and be incorporated into every contract made by CPA Global Limited ("us", "we" and cognate terms) or on our behalf with clients ("you") for the provision of Intellectual property related professional services ("Services") and shall subject to condition 1.2 below prevail over any terms or conditions contained or referred to in any documents submitted by you or previously submitted by us or in correspondence or elsewhere.

1.2 The details of the Services that we shall provide to you are set out in our operating procedures (the "Operating Procedures"). We may change the Services and/or Operating Procedures at any time upon written notice to you.

1.3 A variation of these conditions is valid only if it is in writing and signed by or on behalf of us.

1.4 No failure to enforce or delay in enforcing any of these conditions shall operate as a waiver of any of them and no partial or single exercise shall prevent any other or future exercise of that or any other right.

2. FORMATION OF CONTRACT

2.1 A contract shall arise between us on whichever is the earlier of our actual receipt of your instructions to act or a renewal notice issued by us and our acting upon your instructions.

2.2 Our acceptance of any oral instructions from you shall be effective only when such instructions have been confirmed in writing by letter or facsimile transmission. Electronic instructions will be accepted only if by the CPA Direct System to which separate conditions apply, or by an electronic interface approved by us.

3. INSTRUCTIONS

3.1 A condition to our acting on your behalf will be that you respond promptly, clearly and completely to any request we may make for instructions, information, technical data, documents and payment of charges.

3.2 Without prejudice to the need for you to respond promptly, if we need your response by a specific deadline we will endeavour to say so when seeking instructions. If you miss a deadline or send us insufficiently clear or timely or incomplete instructions we shall have no liability for any loss which may arise and we shall not be under any obligation to take any steps to preserve or to protect your rights further. Nevertheless, if at our sole discretion we take any such steps, then you shall pay us for all charges, cost of work done, overheads and disbursements incurred, each of which may include premia and/or special charges to reflect urgency and disruption.

3.3 You agree that we may rely and act upon instructions from your authorised agent whose

details you have supplied to us until we receive your written signed instructions to the contrary.

3.4 Subject to these conditions we will proceed on the basis that our duty to you is to do what we consider is necessary properly to protect and preserve your rights.

4. AGENTS AND OTHER SUB-CONTRACTORS

4.1 In order to provide the Services we may need to instruct local agents practising in the jurisdiction of each relevant registry or other independent specialist providers. The naming of any third party referral firm(s) in our correspondence is not intended to give rise to any agency relationship. Each party is intended to be a principal in its own right and the contract for the Services is between you and us only, in accordance with these conditions.

5. CHARGES

5.1 You shall pay the Service Charge for the Services as set out in Clause 4 of the Operating Procedures.

5.2 You shall also pay our charges comprising our estimate of our charges in respect of submission to the relevant registries in each jurisdiction ("Official Charge") and which vary from time to time and, where applicable a "Country Charge" which is set out in a tariff (which may vary from time to time), a current copy of which is available on request.

5.3 Any sums of money that may at any time require to be converted from one currency into the currency in which we have agreed to invoice you will be so converted at our rates from time to time and be subject to a charge for managing such funds.

5.4 All charges are subject to variation in the light of changes to underlying charges and/or for correction of errors. In addition, we shall be entitled to increase our charges once each year by no more than the greater of 5% or the U.S. Consumer Price Index.

5.5 On each occasion upon which we send you a renewal notice in relation to the renewal of a particular Intellectual property right we give you our best estimate of the likely total aggregate charges likely to be payable in respect thereof (including the Service Charge, the Country Charge and the Official Charge) on the basis that the transaction proceeds in an expected and standard manner. Your instruction to us to proceed (whether express or, if otherwise so agreed, by failure to instruct us not to proceed) shall constitute your acceptance of, and agreement to pay such fee and, if applicable, to pay later after they have arisen and been invoiced any supplements thereto that may arise or become appropriate in the light of any unexpected work, change of circumstances or further expenses becoming necessary. We shall submit to you an invoice for the amount of such

CPA GLOBAL

- estimate after your instruction or deemed instruction to us to proceed.
- 5.6 VAT and any other relevant tax or duty payable, if any, by you on our supply of Services shall be added to all fees.
- 5.7 You acknowledge that it is our policy not to pay accumulated annuities or back fees arising in certain countries at the time of grant or acceptance of an application, and it is your responsibility to arrange payment of such fees directly with your associate.
6. **PAYMENT**
- 6.1 Unless otherwise agreed, payment of Invoices shall be made in full within 30 days from the date that our Invoice is issued. Time shall be of the essence of payment. Interest will be charged on any amounts overdue at the rate of 1% per month or part thereof. We may suspend the supply of Services to you where any amounts are overdue under any contract until all such amounts have been paid.
- 6.2 If in our opinion your creditworthiness deteriorates before completion of performance of our Services we may require full or partial payment of all or any fees prior to performance or the provision of security by you in a form acceptable to us.
- 6.3 We shall be entitled to offset any amount owing to us from you against any amount owed to you by us.
7. **CONFIDENTIALITY**
- 7.1 Each of you and we undertake to the other that it will not during the term of this agreement or at any time thereafter use, divulge or communicate to any person, except its professional representatives or advisers or as may be required by law or any legal or regulatory authority or pursuant to performance of its obligations under a contract made pursuant hereto, any confidential information relating to the other's business, financial or other affairs which is not in the public domain concerning the other party which may have, or may in future, come to its knowledge under the provisions hereof and each of you and we shall use reasonable endeavours to prevent the publication or disclosure of any such information. This provision shall not apply to information already known to the receiving party prior to its receipt hereunder or which subsequently comes into the public domain or its knowledge other than as a result of a breach hereof.
8. **RECORDS**
- 8.1 We will maintain records in connection with all matters in respect of which we provide the Services to you. Any file which we may open in connection with the Services shall be and shall remain our property at all times. When we have completed the contract for the Services in respect of any matter we may destroy any related file at any time after the expiry of one year.
- 8.2 If you wish to have access to any of our files after we have ceased to act for you then, provided that such file has not already been destroyed pursuant to condition 8.1 above, we shall be entitled to require you to make payment of any monies then still due from you to us and in addition to charge you a reasonable fee for the work involved in giving you such access.
9. **TERMINATION**
- 9.1 Unless otherwise agreed, either you or we may terminate our provision of the Services by giving to the other not less than one year's notice in writing expiring at any time.
- 9.2 On or at any time after the occurrence of any of the events in condition 9.3, we may suspend further performance of Services for you and/or terminate any contract with you with immediate effect by written notice to you.
- 9.3 The events are:
- (a) you being in breach of an obligation under a contract with us;
 - (b) you passing a resolution for your winding up or a court of competent jurisdiction making an order for your winding up or dissolution;
 - (c) your entering administration, the making of an administration order in relation to you or the appointment of a receiver over, or an encumbrancer taking possession of or selling, any of your assets;
 - (d) your making an arrangement or composition with your creditors generally or applying to a court of competent jurisdiction for protection from your creditors.
- 9.4 Upon any termination, any of your indebtedness to us shall become immediately due and payable and we shall be under no further obligation to provide any Services to you.
10. **FORCE MAJEURE**
- 10.1 Where a Force Majeure Event takes place we shall use our reasonable endeavours to carry out the Services.
- 10.2 Notwithstanding 10.1 above, if we are prevented, hindered or delayed from or in supplying any Services in accordance with these conditions by a Force Majeure Event we shall notify you as soon as reasonably possible and we may, at our option:
- (a) suspend performance while the Force Majeure Event continues;
 - (b) apportion available resources between our clients as we decide;
 - (c) terminate any contract so affected with immediate effect by written notice to you;
- and we shall not be liable for any loss or damage suffered by you as a result.
- 10.3 In this condition "Force Majeure Event" means an event or circumstance beyond our reasonable control including, without limitation, strikes,

CPA GLOBAL

lockouts and other industrial disputes relating to our workforce

11 ASSIGNMENT

You may not assign or transfer, or purport to assign or transfer, any of your rights or obligations under a contract without our prior written consent. We may assign, transfer and/or subcontract the whole or any part of this contract without notice to you.

12 GOVERNING LAW

These conditions and any contract made under them shall be governed by and construed in accordance with Virginia law and the courts of Virginia shall have exclusive jurisdiction.

13 NOTICE AND COMMUNICATIONS

Any notice, demand or other communication given or made under or in connection with the matters

contemplated by these conditions shall be in writing and shall be delivered personally or sent by fax or prepaid air mail (to in our case our registered office from time to time marked for the attention of the Secretary) and shall be deemed to have been duly given or made as follows:

- (a) if personally delivered, upon delivery at the address of the relevant party;
- (b) if sent by air mail, 5 days after the date of posting; and
- (c) if sent by fax, when despatched;

provided that if, in accordance with the above provision, any such notice, demand or other communication would otherwise be deemed to be given or made after 5.00 p.m. such notice, demand or other communication shall be deemed to be given or made at 9.00 a.m. on the next usual business day in the place of receipt.

We agree to the above.

Signed for and on behalf of **Eiger Biopharmaceuticals, Inc.**

~~Matthew Bys and Kevin Kaster~~, 350 Cambridge Avenue, Suite 350, Palo Alto, CA 94306

Signature: *Kevin Kaster*

Name: **KEVIN KASTER**

Position: **VP, INTELLECTUAL PROPERTY**

Date: **31 August 2017**

Signed for and on behalf of **CPA Global Limited**

Libration House, Castle Street, Jersey, JE1 1BL, Channel Islands.

Signature: *Amanda Harris*

Name: **Amanda Harris**

Position: **Authorised Signatory**

Date: **- 4 SEP 2017**